The efficacy of dydrogesterone and human menopausal gonadotropin protocol for ART

The efficacy of dydrogesterone and human menopausal gonadotropin protocol for ART - Dydrogesteone new protocol

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029564

Enrollment

400

Registered

2017-10-20

Start date

2016-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

In the study group, patients were administered human menopausal gonadotropin and dydrogesterone per day from day 2 or 3 of the menstrual cycle onward, following ultrasound confirmation of the absence

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Written informed consent is obtained from the patients who are enrolled. Inclusion criteria were as follows: age younger than 41 years, anti-Mullerian hormone (AMH) levels greater than 1.0 ng/ml, first or second time of IVF/intra-cytoplasmic sperm injection (ICSI) at our clinic.

Exclusion criteria

Exclusion criteria: Patients who had endometriosis grade 3 or higher, documented cycles with no oocyte retrieved, and any contraindications to ovarian stimulation treatment.

Design outcomes

Primary

Measure	Time frame
The clinical pregnancy rate	—

Secondary

Measure	Time frame
The number of oocytes retrieved, the fertilization rate, the incidence of premature LH surge, the rate of viable embryos, the ongoing pregnancy rate	—

Countries

Japan

Contacts

Public ContactNanako Iwami

Kamiya Ladies Clinic Reproductive therapy

nanakoiwami@gmail.com011-231-2722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026